ArticleJournal of clinical & translational endocrinology2026
Remnant cholesterol inflammatory index and MASLD in U.S. adults: mediation role of triglyceride-glucose index.
Article in Journal of clinical & translational endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by dyslipidemia and chronic inflammation. We proposed a novel biomarker, the Remnant Cholesterol Inflammatory Index (RCII), and evaluated its association with MASLD, considering mediation via insulin resistance (TyG index). Methods: In 3,232 U.S. adults from NHANES 2015-2020 (709 with MASLD), participants were divided into RCII tertiles. Multivariable logistic regression, restricted cubic splines, threshold analysis, subgroup interaction tests, ROC curves, XGBoost SHAP, and mediation analysis were used to assess relationships and mechanisms. Results: Compared with the lowest tertile, the highest RCII tertile had an OR of 9.578 (95 % CI 6.420-14.291; Conclusions: RCII is a robust lipid-inflammation marker that outperforms conventional lipids in predicting MASLD. Its association is partly mediated by insulin resistance, supporting RCII's use in MASLD risk stratification and early prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.